Samsung Electronics 005930.KS unveiled its latest premium smartphones on Wednesday, in a test of its brand power as the market for mobiles undergoes unprecedented contraction.
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $16
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $18 to $16.